A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mayo Clinic
• Treatments: Bupivacaine

Criteria

Inclusion Criteria

• Adult female patients (18-70 years old) with symptomatic macromastia scheduled for breast reduction using a Wise pattern incision design.

Exclusion Criteria

• Inability to provide informed consent

• Medical or surgical history precluding breast reduction

• History of significant chronic pain requiring daily use of opioid or nonopioid analgesics

• Pregnancy

• Concomitant non-breast surgical procedure

• Previous chest wall irradiation

• Previous breast implant, breast reduction or breast lift surgery

• Known allergy to bupivacaine or liposomal bupivacaine

• Liver or kidney dysfunction

• Use of antiplatelet or anticoagulation therapy.